Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.88 | 1.36 |
NAV | ₹796.69 | ₹199.50 |
Fund Started | 10 Sep 2002 | 07 May 2007 |
Fund Size | ₹6007.60 Cr | ₹84854.73 Cr |
Exit Load | Exit load of 1%, if redeemed within 90 days. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | -2.83% | 4.60% |
3 Year | 19.81% | 26.42% |
5 Year | 24.59% | 29.95% |
1 Year
3 Year
5 Year
Equity | 98.05% | 93.60% |
Cash | 1.95% | 6.40% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
AU Small Finance Bank Ltd. | 3.42% |
Max Financial Services Ltd. | 3.21% |
Fortis Healthcare Ltd. | 2.73% |
APL Apollo Tubes Ltd. | 2.68% |
K.P.R. Mill Ltd. | 2.66% |
Thermax Ltd. | 2.60% |
The Federal Bank Ltd. | 2.40% |
JK Cement Ltd. | 2.31% |
Prestige Estates Projects Ltd. | 2.30% |
Torrent Power Ltd. | 2.23% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.76% |
Balkrishna Industries Ltd. | 3.54% |
Indian Bank | 3.26% |
Fortis Healthcare Ltd. | 3.18% |
AU Small Finance Bank Ltd. | 3.16% |
Coforge Ltd. | 2.93% |
The Federal Bank Ltd. | 2.91% |
Hindustan Petroleum Corporation Ltd. | 2.90% |
Glenmark Pharmaceuticals Ltd. | 2.87% |
Ipca Laboratories Ltd. | 2.80% |
Name | Dhaval Joshi | Chirag Setalvad |
Start Date | 10 Jun 2024 | 28 Jun 2014 |
Name
Start Date
Description | The scheme aims at long-term growth of capital at controlled level of risk by investing primarily in mid-cap stocks, to generate returns higher than a fund focused on large and liquid stocks. A small portion of the portfolio may be kept in call & money market instruments in order to meet the liquidity needs. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 10 Sep 2002 | 07 May 2007 |
Description
Launch Date